Drug Profile
BACE1 protein inhibitor - Eli Lilly and Company
Alternative Names: 2434074; LSN 2434074; LY-2434074Latest Information Update: 19 Apr 2016
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class
- Mechanism of Action BACE1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 18 Oct 2010 Phase-I clinical trials in Alzheimer's disease (PO)
- 29 Sep 2006 Data presented at the 232nd American Chemical Society National Meeting (232nd-ACS-2006) have been added to the Alzheimer's disease and Cognition disorders pharmacodynamics section
- 24 Jul 2006 Preclinical trials in Alzheimer's disease in Spain (PO)